The CACNA1C gene polymorphism and Effect of Some Antihypertensive Medication on Cardiac Function Markers in Hypertension Patients
CACNA1C gene polymorphism and Effect of Some Antihypertensive Medication on Cardiac Function
DOI:
https://doi.org/10.63841/31699Keywords:
Antihypertensive medication, cTnI, CK-MB, Myoglobin, CACNA1C, ARB, CCBAbstract
The CACNA1C gene affects calcium flow in heart and vessel cells, variants in this gene can alter calcium handling, influencing vascular tone and cardiac contractility, thereby contributing to the development and progression of hypertension. This study aims to evaluate the variation in serum levels of creatine kinase-MB(CK-MB), myoglobin, and cardiac troponin I among hypertensive patients, and to determine whether these levels show a marked difference among individuals receiving antihypertensive therapy in hypertensive patients and untreated healthy controls. It also examines CACNA1C gene variation between HTN patients and healthy explore its potential role in hypertension and cardiac biomarker levels.
The study utilized a cross-sectional design and was conducted at Shahid Dr. Khalid Teaching Hospital in Koya, Erbil. A total of 75 participants were enrolled, including 55 individuals diagnosed with hypertension and 20 healthy controls. The investigation involved measuring cardiac biomarkers such as Troponin I, CK-MB, and Myoglobin. Additionally, PCR amplification of the CACNA1C gene was carried out using DNA extracted from blood samples, prepared with the Beta Bayern Tissue and Blood DNA Preparation Kit, at the research center of Erbil International University. The analysis between groups and diabetes duration was performed through GraphPad Prism 10.
The results showed non-significant difference in troponin I level between the CCB and ARB groups. A significant reduction in myoglobin level was observed in the ARB group compared to the CCB group. Nevertheless, there were non-significant differences between the control group and either the CCB or ARB groups. There were non-significant differences in CK-MB level between any of the groups. This suggests that CK-MB concentrations remained similar regardless of treatment groups. Additionally, genetic result the control group showed no variation in rs1051375 (all G/G), whereas both the CCB and ARB patient groups exhibited SNP variation, including G/A and A/A genotypes. This finding indicates a potential link between the polymorphism and hypertension or its treatment response.
The CACNA1C rs1051375 genotype distribution differed between controls and hypertensive patients, with a shift toward the A allele, especially in those on CCBs. ARB treatment showed greater reduction in myoglobin levels, suggesting better cardio protection. These findings support the role of genetic markers and biomarkers in guiding personalized hypertension therapy.
Downloads
References
B. Zhou, P. Perel, G. A. Mensah, and M. Ezzati, "Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension," Nature Reviews Cardiology, vol. 18, no. 11, pp. 785-802, 2021.
J. H. Kim and R. Thiruvengadam, "Hypertension in an ageing population: Diagnosis, mechanisms, collateral health risks, treatments, and clinical challenges," Ageing Research Reviews, vol. 98, p. 102344, 2024.
J. Rysz, B. Franczyk, M. Rysz-Górzyńska, and A. Gluba-Brzózka, "Pharmacogenomics of Hypertension Treatment," International Journal of Molecular Sciences, vol. 21, no. 13, 2020.
B. G. Schultz, J. Tilton, J. Jun, T. Scott-Horton, D. Quach, and D. R. Touchette, "Cost-effectiveness analysis of a pharmacist-led medication therapy management program: hypertension management," Value in Health, vol. 24, no. 4, pp. 522-529, 2021.
A. C. Flint et al., "Effect of systolic and diastolic blood pressure on cardiovascular outcomes," New England Journal of Medicine, vol. 381, no. 3, pp. 243-251, 2019.
M. A. Alzaabi et al., "Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review," Card Fail Rev, vol. 10, p. e06, 2024.
L. M. Brewster, F. A. Karamat, and G. van Montfrans, "Creatine kinase and blood pressure: a systematic review," Medical Sciences, vol. 7, no. 4, p. 58, 2019.
S. Sukul, J. Bahinipati, S. Patra, and K. Ravichandran, "Serum creatine kinase activity among hypertensive patients and its role as a predictor for failure of antihypertensive treatment," Journal of Clinical & Diagnostic Research, vol. 12, no. 11, pp. 121-5, 2018.
O. Hammarsten, J. Mair, M. Möckel, B. Lindahl, and A. S. Jaffe, "Possible mechanisms behind cardiac troponin elevations," Biomarkers, vol. 23, no. 8, pp. 725-734, 2018.
B. Kang et al., "Elevated myoglobin in patients with primary aldosteronism: a cross-sectional study," Frontiers in Endocrinology, vol. 13, p. 799174, 2022.
P. Welsh et al., "Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes," Circulation, vol. 139, no. 24, pp. 2754-2764, 2019.
K. E. Jones et al., "The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations," Curr Issues Mol Biol, vol. 46, no. 7, pp. 6315-6327, Jun 22 2024.
W. J. Choi et al., "Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers," J. Korean Med. Sci, vol. 37, no. 33, pp. e255-0, 08 2022.
P. K. Whelton et al., "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines," Hypertension, vol. 71, no. 6, pp. e13-e115, Jun 2018.
L. Chen et al., "Association Between CACNA1C Polymorphisms and Insomnia in a Chinese Han Population: A Case-Control Population-Based Analysis," 2021.
J. A. Hennessey et al., "A CACNA1C variant associated with reduced voltage-dependent inactivation, increased CaV1.2 channel window current, and arrhythmogenesis," PLoS One, vol. 9, no. 9, p. e106982, 2014.
F. Rahman, N. Muthaiah, and G. Kumaramanickavel, "Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension," Indian Journal of Pharmacology, vol. 53, no. 4, pp. 301-309, 2021.
W. J. Elliott and C. V. Ram, "Calcium channel blockers," J Clin Hypertens (Greenwich), vol. 13, no. 9, pp. 687-9, Sep 2011.
H. S. Jeong et al., "Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up," Scientific Reports, vol. 11, no. 1, p. 1783, 2021.
F. Hassan, J. D. James, H. O. K. James, and J. L. Carl, "Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes," Open Heart, vol. 3, no. 2, p. e000473, 2016.
B. H. M. Correa, C. R. Moreira, M. E. Hildebrand, and L. B. Vieira, "The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders," Curr Neuropharmacol, vol. 21, no. 2, pp. 183-201, 2023.
K. Jabbari and G. Bernardi, "Cytosine methylation and CpG, TpG (CpA) and TpA frequencies," Gene, vol. 333, pp. 143-9, 2004.
S. Kim, C. H. Cho, D. Geum, and H. J. Lee, "Association of CACNA1C Variants with Bipolar Disorder in the Korean Population," Psychiatry Investig, vol. 13, no. 4, pp. 453-7, 2016.
A. L. Beitelshees et al., "CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response," Circulation: Cardiovascular Genetics, vol. 2, no. 4, pp. 362-370, 2009.
Q. Sun et al., "Impact of CACNA1C polymorphisms on antihypertensive efficacy of calcium channel blocker," Zhonghua Xin Xue Guan Bing Za Zhi, vol. 40, no. 1, pp. 3-7, 2012.
Q. Li et al., "The effects of high pressure treatment on the structural and digestive properties of myoglobin," Food Research International, vol. 156, p. 111193, 2022.
G. S. Kim et al., "Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014)," Korean Circ J, vol. 50, no. 11, pp. 984-994, 2020.
B. Ergün, A. A. Kutlugün, M. Ç. ERGÜN, G. Aktürk, and E. Beyan, "Investigation of the effects of angiotensin converting enzyme inhibitors and angiotensinreceptor blockers on anemia in patients with normal or mildly low glomerular filtrationrate," Turkish journal of medical sciences, vol. 51, no. 6, pp. 3047-3052, 2021.
M. A. Emokpae and G. O. Nwagbara, "Serum creatine kinase-MB isoenzyme activity among subjects with uncomplicated essential hypertension: any sex differences," Medical Sciences, vol. 5, no. 2, p. 8, 2017.
K. Gupta, M. Kiran, S. Chhabra, M. Mehta, and N. Kumar, "Prevalence, Determinants and Clinical Significance of Cardiac Troponin-I Elevation among Individuals with Hypertensive Emergency: A Prospective Observational Study," Indian J Crit Care Med, vol. 26, no. 7, pp. 786-790, 2022.
E. P. Odum and E. E. Young, "Elevated cardiac troponin I, creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 12, no. 2, pp. 141-145.
V. L. Aengevaeren et al., "Exercise-Induced Cardiac Troponin Elevations: From Underlying Mechanisms to Clinical Relevance," Circulation, vol. 144, no. 24, pp. 1955-1972, 2021.
L. Minuzzo, E. S. Santos, and A. Timerman, "Association between angiotensin-converting enzyme inhibitors and troponin in acute coronary syndrome," Arq Bras Cardiol, vol. 103, no. 6, pp. 513-20, 2014.
E. Kutumova, A. Kovaleva, R. Sharipov, G. Lifshits, and F. Kolpakov, "Mathematical modelling of the influence of ACE I/D polymorphism on blood pressure and antihypertensive therapy," Heliyon, vol. 10, no. 9, p. e29988, 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Academic Journal of International University of Erbil
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
